CAMP4 Therapeutics Corporation
CAMPHealthcare|Biotechnology|US
$4.06
+0.34 (+9.14%)
Tangible Book / Share
$1.36
Cash / Share
$1.58
About
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Stock Price
-8.8%(1Y)
1M
+9.7%
3M
-4.2%
6M
-9.0%
YTD
-33.8%
1Y
-2.4%
3Y
-62.1%
5Y
-62.1%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Active: 1
Active Trials (1)
Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype
NCT06247670Healthy Volunteers
Phase 1Active
Enrollment: 120 participants
Key Facts
Market Cap$254.8M
Employees48 (-13% YoY)
CEOJoshua Mandel-Brehm
IPO DateOct 11, 2024
Beta0.21
52-Week Range$2.9 – $7.75
Avg Volume237,866
ExchangeNASDAQ
Websitecamp4tx.com
Ownership
Float69.1%
Shares Outstanding62.8M
Recent Insider Trades
Gold KellyBUY
Aug 31, 202610,000 shares @ $3.96
Schwab Andrew J.SELL
Aug 27, 2026400,000 shares @ $4.04
Schwab Andrew J.SELL
Aug 24, 202610 shares @ $4.50
Schwab Andrew J.SELL
Aug 19, 202645,147 shares @ $4.76
Schwab Andrew J.SELL
Aug 20, 2026114,700 shares @ $4.54
Peers
Recent News
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
Nov 5, 2026 · zacks.com
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
Nov 5, 2026 · globenewswire.com
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Oct 29, 2026 · zacks.com
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
Oct 27, 2026 · globenewswire.com
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
Oct 20, 2026 · marketbeat.com
Data last updated: Nov 9, 2026, 04:01 AM